Life Science

The M & A frenzy in Life Sciences

During the last years we have witnessed a strong increase in mergers and acquisitions within the Life Sciences industry, especially in pharma and biotech. According to a Thomson One and KPMG analysis, the total deal value of the M&A dealings of the first half of 2015 was $ 221 bn.
The biggest M&A issues recently have been Shire´s $ 32 bn merger with Baxalta, which created the global market leader in rare diseases and other specialised disorders, generic maker Teva´s purchase of the generics division of Allergan for $ 40.5 bn and Bayer´s takeover bid of $ 66 bn for U.S. seeds company Monsanto.

Continue reading

scroll top